[Evaluation of the liver cell clearance fraction before and after treatment with alpha-mercaptopropionylglycine in chronic hepatopathies].
The effectiveness of alpha-MPG management was evaluated in terms of changes in the liver cell depuration fraction in patients who presented reduced a levels. There was a marked improvement occasionally to the point of normalisation, in patients with toxic hepatosis. Variations were less significant in cirrhosis, especially in patients with a very low liver metabolism flow. No conclusions could be draw in the case of subjects with chronic heaptitis of various aetiology, since their DF was normal under basal conditions. It seems reasonable to suppose that further improvements are obtainable from prolonged administration of the drug.
D000603:Amino Acids, Sulfur / Q000627:therapeutic use*; D002908:Chronic Disease; D006050:Gold Radioisotopes; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D013448:Sulfobromophthalein; D008625:Tiopronin / Q000627:therapeutic use*
D000603:Amino Acids, Sulfur; D006050:Gold Radioisotopes; D013448:Sulfobromophthalein; D008625:Tiopronin
Valutazione della frazione di depurazione epatocitaria prima e dopo trattamento con alfa-mercaptopropionilglicina nelle epatopatie croniche.